In fact, while the WARSS study did not show any benefit of warfarin over aspirin in reducing the 2-year risk of stroke or death, a post hoc analysis of WARSS showed that in patients with NT-proBNP >750 ng/dL, a biomarker of atrial cardiopathy, warfarin was superior to aspirin in reducing the risk of stroke or death at 2 years (28). This evidence concerns the gene NPPB and stroke disorder.